Table 1 Demographic data for control group and those receiving a dose of Sugammadex following primary reversal with neostigmine
Control Group Neostigmine Only n = 49,820 n, (%) | Neostigmine + Sugammadex n = 1660 n, (%) | P Value | |
|---|---|---|---|
Age (years) (median [IQR]) | 56.40 [42.20, 67.61] | 61.9 [50.9, 71.2] | < 0.001 |
Body mass index (median [IQR]) | 28.70 [24.55, 33.23] | 30.0 [25.84, 35.4] | < 0.001 |
ASA Physical Status | < 0.001 | ||
ASA 1 or 2 | 18,375 (36.9) | 272 (16.4) | |
ASA 3 | 27,322 (54.8) | 1088 (65.5) | |
ASA 4 | 4123 (8.3) | 300 (18.1) | |
Inpatient | 11,899 (23.9) | 564 (34.0) | < 0.001 |
Emergency case status | 6721 (13.5) | 395 (23.8) | < 0.001 |
Female | 24,613 (49.4) | 777 (46.8) | 0.042 |
Neuromuscular disease | 396 (0.8) | 22 (1.3) | 0.026 |
After hours cases | 2209 (4.4) | 135 (8.1) | < 0.001 |
End-stage renal disease | 445 (0.9) | 38 (2.3) | < 0.001 |
Race | < 0.001 | ||
African American | 7640 (15.3) | 378 (22.8) | |
Other | 3349 (6.7) | 84 (5.1) | |
Caucasian | 38,831 (77.9) | 1198 (72.2) | |
Ethnicity Hispanic | 2319 (4.7) | 55 (3.3) | |
Case duration (min) (median [IQR]) | 175.00 [126.00, 243.00] | 165.5[115,249] | 0.002 |
Surgical Procedure Class | < 0.001 | ||
Abdominal/General | 12,544 (25.2) | 579 (34.9) | |
Burn surgery | 454 (0.9) | 15 (0.9) | |
Cardiac surgery | 123 (0.2) | 7 (0.4) | |
ENT surgery | 7053 (14.2) | 148 (8.9) | |
Neurosurgery | 2033 (4.1) | 68 (4.1) | |
Non-operating room anesthesia | 1515 (3.0) | 58 (3.5) | |
Orthopaedic surgery | 12,717 (25.5) | 282 (17.0) | |
Plastic surgery | 394 (0.8) | 99 (6.0) | |
Thoracic surgery | 4342 (8.7) | 79 (4.8) | |
Urogynecologic surgery | 1248 (2.5) | 251 (15.1) | |
Vascular surgery | 6194 (12.4) | 63 (3.8) | |
Other surgical procedures | 1203 (2.4) | 11 (0.7) | |
Qualitative train of four (TOF) | < 0.001 | ||
TOF = 0 | 7670 (15.4) | 161 (9.7) | |
TOF = 1 | 41,887 (84.1) | 534 (32.2) | |
TOF = 2 | 7933 (15.9) | 390 (23.5) | |
TOF = 3 | 45,676 (91.7) | 120 (7.2) | |
TOF = 4 | 4144 (8.3) | 455 (27.4) | |
Rocuronium redosed | 35,036 (70.3) | 1289 (77.7) | < 0.001 |
Rocuronium dose > 0.43 mg/kg/hr | 21,901 (44.0) | 984 (59.3) | < 0.001 |
Primary reversal with neostigmine < 48 min after last dose of rocuronium | 22,328 (44.8) | 1024 (61.7) | < 0.001 |
Neostigmine dose (mg) (median, [IQR]) | 4.00 [4.00, 5.00] | 5.0 [4.0, 5.0] | < 0.001 |
Time between neostigmine and extubation (min) (median, [IQR]) | 10.00 [7.00, 16.00] | 13 [9, 19] | < 0.001 |